中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Viral Diseases
NASH/PBC
Cancer
Exploratory Indications
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
Investors
Financials & Filing
Presentation Materials
Next Day Disclosure Returns - Share Buyback
2023-09-26
Voluntary Announcement - Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
2023-09-26
Next Day Disclosure Returns - Share Buyback
2023-09-25
Next Day Disclosure Returns - Share Buyback
2023-09-21
Next Day Disclosure Returns - Share Buyback
2023-09-20
Next Day Disclosure Returns - Share Buyback
2023-09-18
Next Day Disclosure Returns - Share Buyback
2023-09-15
Next Day Disclosure Returns - Share Buyback
2023-09-14
Next Day Disclosure Returns - Share Buyback
2023-09-13
Next Day Disclosure Returns - Share Buyback
2023-09-12
1
2
3
4
»
浙公网安备 33010802003344号
浙ICP备11050387号-1
